MPM Oncology Impact Management »

Liquidia Technologies shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Liquidia Technologies (LQDA) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Liquidia Technologies

Tip: Access up to 7 years of quarterly data

All positions including Liquidia Technologies held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Liquidia Technologies by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $4.5M 200k 22.74

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Liquidia Technologies

Farallon Capital Management
Caligan Partners
BlackRock
Findell Capital Management
Vanguard Group
Susquehanna International
Goldman Sachs Group
Opaleye Management
Jane Street
Caption Management
Point72 Asset Management
State Street Corporation
TCG Crossover Management
Caprock
Geode Capital Management

View all funds holding Liquidia Technologies